Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma

Oncologist

Volumn 19, Issue 8, 2014, Pages 790-796

  Dreno, Brigitte ^a   Basset Seguin, Nicole ^b   Caro, Ivor ^c   Yue, Huibin ^c   Schadendorf, Dirk ^d  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c GENENTECH INC   (United States)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Advanced basal cell carcinomax; Clinical benefit; ERIVANCE BCC; Independent panel review; Vismodegibx

Indexed keywords

VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

ARTICLE; BASAL CELL CARCINOMA; CLINICAL ASSESSMENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; ADULT; AGED; CANCER STAGING; CARCINOMA, BASAL CELL; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; FEMALE; MALE; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOPLASM STAGING; PYRIDINES;

EID: 84905485738     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0003     Document Type: Article

References (27)

1. Genetics of skin cancer (PDQ): Basal cell carcinoma. Available at http: //www. cancer. gov/ cancertopics/pdq/genetics/skin/HealthProfessional/ page2. Accessed June 25, 2014.
2. Lear JT, Smith AG. Basal cell carcinoma. Postgrad Med J 1997; 73: 538-542.
3. Walling HW, Fosko SW, Geraminejad PA et al. Aggressive basal cell carcinoma: Presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23: 389-402.
4. Von Hoff DD, LoRusso PM, Rudin CM et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361: 1164-1172.
5. Mohan SV, Chang ALS. Advanced basal cell carcinoma: Epidemiology and therapeutic innovations. Curr Dermatol Rep 2014; 3: 40-45.
6. Danial C, Lingala B, Balise R et al. Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. Br J Dermatol 2013; 169: 673-676.
7. Moser S, Borm J, Mihic-Probst D et al. Metastatic basal cell carcinoma: Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; 117: e79-e82.
8. Soleymani AD, Scheinfeld N, Vasil K et al. Metastatic basal cell carcinoma presenting with unilateral upper extremity edema and lymphatic spread. J Am Acad Dermatol 2008; 59(suppl 1): S1-S3.
9. Amin SH, Tibes R, Kim JE et al. Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. Laryngoscope 2010; 120: 2456-2459.
10. Varga E, Korom I, Raskó Z et al. Neglected basal cell carcinomas in the 21st century. J Skin Cancer 2011; 392151.
11. Göppner D, Leverkus M. Basal cell carcinoma: From the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer 2011; 650258.
12. Cirrone F, Harris CS. Vismodegib and the hedgehog pathway: A new treatment for basal cell carcinoma. Clin Ther 2012; 34: 2039-2050.
13. Reifenberger J, Wolter M, Weber RG et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998; 58: 1798-1803.
14. Xie J, Murone M, Luoh SM et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391: 90-92.
15. Daya-Grosjean L, Couvé-Privat S. Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett 2005; 225: 181-192.
16. Caro I, Low JA. The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res 2010; 16: 3335-3339.
17. Sekulic A, Migden MR, Oro AE et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-2179.
18. Sekulic A, Migden MR, Oro AE et al. Efficacy and safety of vismodegib in patients with advanced basal cell carcinoma (aBCC): 12-month updateof the ERIVANCE BCC study. Poster presented at: Society for Melanoma Research 2012 Congress; November 8-11, 2012; Hollywood, CA.
19. Johnson JR, Williams G, Pazdur R. End points andUnited States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003; 21: 1404-1411.
20. Erasmus JJ, Gladish GW, Broemeling L et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: Implications for assessment of tumor response. J Clin Oncol 2003; 21: 2574-2582.
21. Vos MJ, Uitdehaag BM, Barkhof F et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 2003; 60: 826-830.
22. Watanabe H, Kunitoh H, Yamamoto S et al. Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients. Cancer Sci 2006; 97: 214-218.
23. Common Terminology Criteria for AdverseEvents v3.0 (CTCAE). Available at http: //ctep. cancer. gov/ protocolDevelopment/electronic_applications/docs/ ctcaev3. pdf. Accessed May 14, 2013.
24. Fleiss JL. Statistical Methods for Rates and Proportions. 3rd ed. New York, NY: John Wiley & Sons, Inc., 2003.
25. Kendall MG. Rank Correlation Methods. 2nd ed. London, U. K.: Charles Griffin & Co. Ltd., 1955.
26. Agresti A. Categorical Data Analysis. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc, 2002.
27. Axelson M, Liu K, Jiang X et al. U. S. Food and Drug Administration approval: Vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res 2013; 19: 2289-2293.